Literature DB >> 33471716

Deterioration in Motor Function Over Time in Older Adults With Type 2 Diabetes is Associated with Accelerated Cognitive Decline.

Ithamar Ganmore1, Isak Elkayam2, Ramit Ravona-Springer3, Hung-Mo Lin4, Xiaoyu Liu4, Meir Plotnik5, Aron S Buchman6, Yuval Berman1, Jonathan Schwartz1, Mary Sano7, Anthony Heymann8, Michal Schnaider Beeri9.   

Abstract

OBJECTIVE: Type 2 diabetes (T2D) is associated with motor impairments and a higher dementia risk. The relationships of motor decline with cognitive decline in T2D older adults has rarely been studied. Using data from the Israel Diabetes and Cognitive Decline study (N = 892), we examined associations of decline in motor function with cognitive decline over a 54-month period.
METHODS: Motor function measures were strength (handgrip) and gait speed (time to walk 3 m). Participants completed a neuropsychologic battery of 13 tests transformed into z-scores, summarized into 4 cognitive domains: episodic memory, attention/working memory, executive functions, and language/semantic categorization. The average of the 4 domains' z-scores defined global cognition. Motor and cognitive functions were assessed in 18-months intervals. A random coefficients model delineated longitudinal relationships of cognitive decline with baseline and change from baseline in motor function, adjusting for sociodemographic, cardiovascular, and T2D-related covariates.
RESULTS: Slower baseline gait speed levels were significantly associated with more rapid decline in global cognition (P = .004), language/semantic categorization (P = .006) and episodic memory (P = .029). Greater decline over time in gait speed was associated with an accelerated rate of decline in global cognition (P = .050), attention/working memory (P = .047) and language/semantic categorization (P<.001). Baseline strength levels were not associated with cognitive decline but the rate of declining strength was associated with an accelerated decline in executive functions (P = .025) and language/semantic categorization (P = .006).
CONCLUSION: In T2D older adults, the rate of decline in motor function, beyond baseline levels, was associated with accelerated cognitive decline, suggesting that cognitive and motor decline share common neuropathologic mechanisms in T2D.
© 2020 American Association of Clinical Endocrinologists. Published by Elsevier, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33471716     DOI: 10.4158/EP-2020-0289

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  5 in total

1.  Diagnosis of TCM symptoms and analysis of risk factors of mild cognitive impairment in patients with type 2 diabetes mellitus.

Authors:  Xudong Fu; Jiajia Wang; Ping Zhang; Hongquan Du; Suqin Wu; Haiqing Zhang; Wen Xiong
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

2.  Sarcopenia is associated with incident Alzheimer's dementia, mild cognitive impairment, and cognitive decline.

Authors:  Michal S Beeri; Sue E Leugrans; Osvaldo Delbono; David A Bennett; Aron S Buchman
Journal:  J Am Geriatr Soc       Date:  2021-05-05       Impact factor: 7.538

3.  Diverse Motor Performances Are Related to Incident Cognitive Impairment in Community-Dwelling Older Adults.

Authors:  Michal Schnaider Beeri; Sue E Leurgans; David A Bennett; Lisa L Barnes; Aron S Buchman
Journal:  Front Aging Neurosci       Date:  2021-09-30       Impact factor: 5.702

4.  Alzheimer's Disease Polygenic Risk Score Is Not Associated With Cognitive Decline Among Older Adults With Type 2 Diabetes.

Authors:  Sigalit B Manzali; Eric Yu; Ramit Ravona-Springer; Abigail Livny; Sapir Golan; Yuxia Ouyang; Orit Lesman-Segev; Lang Liu; Ithamar Ganmore; Anna Alkelai; Ziv Gan-Or; Hung-Mo Lin; Anthony Heymann; Michal Schnaider Beeri; Lior Greenbaum
Journal:  Front Aging Neurosci       Date:  2022-08-30       Impact factor: 5.702

5.  Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults.

Authors:  Pasquale Mone; Jessica Gambardella; Angela Lombardi; Antonella Pansini; Stefano De Gennaro; Anna Luisa Leo; Michele Famiglietti; Anna Marro; Maria Morgante; Salvatore Frullone; Antonio De Luca; Gaetano Santulli
Journal:  Cardiovasc Diabetol       Date:  2022-01-19       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.